TY - JOUR
T1 - Alteplase Treatment in Acute Stroke
T2 - Incorporating Food and Drug Administration Prescribing Information into Existing Acute Stroke Management Guide
AU - Demaerschalk, Bart M
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Despite strong evidence that intravenous tissue plasminogen activator (tPA) improves outcomes in acute ischemic stroke patients, its use in clinical practice remains modest. Complex eligibility criteria have been postulated as barriers to greater utilization. Further complicating this has been multiple guidelines and prescribing labels that have been published since first being approved for use in 1996. In this review, several warning and exclusion criteria for tPA in acute ischemic stroke are reviewed with the goal of providing readers a nuanced understanding of historical context and available evidence to make informed decision.
AB - Despite strong evidence that intravenous tissue plasminogen activator (tPA) improves outcomes in acute ischemic stroke patients, its use in clinical practice remains modest. Complex eligibility criteria have been postulated as barriers to greater utilization. Further complicating this has been multiple guidelines and prescribing labels that have been published since first being approved for use in 1996. In this review, several warning and exclusion criteria for tPA in acute ischemic stroke are reviewed with the goal of providing readers a nuanced understanding of historical context and available evidence to make informed decision.
KW - Alteplase
KW - Food and Drug Administration
KW - Guidelines
KW - Ischemic stroke
KW - Tissue plasminogen activator
UR - http://www.scopus.com/inward/record.url?scp=84977623896&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84977623896&partnerID=8YFLogxK
U2 - 10.1007/s11883-016-0602-5
DO - 10.1007/s11883-016-0602-5
M3 - Review article
C2 - 27363696
AN - SCOPUS:84977623896
VL - 18
JO - Current Atherosclerosis Reports
JF - Current Atherosclerosis Reports
SN - 1523-3804
IS - 8
M1 - 53
ER -